口服万古霉素对原发性硬化性胆管炎肝脏相关终点无显著影响:随机安慰剂对照试验
这项3期、18个月、双盲、安慰剂对照试验纳入82例原发性硬化性胆管炎(PSC)成人患者,随机接受口服万古霉素(OV,125–375 mg 每日4次)或安慰剂。主要终点血清碱性磷酸酶(SAP)正常化率两组相似(5% vs 6.7%,P=1.00),OV组SAP降幅更大(+1.2% vs -21.9%,P=0.03),但Mayo PSC风险评分和肝硬度变化无差异。OV最常见副作用为牙齿和舌变色(17.5%)。
要点
- 口服万古霉素未显著提高PSC患者SAP正常化率(5% vs 6.7%,P=1.00)。
- OV组SAP降幅更大(-21.9% vs +1.2%,P=0.03),但Mayo风险评分和肝硬度无改善。
- 牙齿和舌变色是OV最常见副作用(17.5%)。
核心结论
- 口服万古霉素与PSC疾病严重程度标志物的临床显著降低无关。
研究设计与样本
- 3期、18个月、双盲、安慰剂对照试验,纳入82例SAP大于正常上限1.5倍的PSC成人患者。
- 随机分配至安慰剂或口服万古霉素(125–375 mg 每日4次,根据生化应答调整)。
- 73例患者至少完成一次结局评估。
主要发现
- 18个月后SAP正常化率安慰剂组5%、OV组6.7%(P=1.00)。
- SAP变化安慰剂组+1.2%、OV组-21.9%(P=0.03)。
- Mayo PSC风险评分变化安慰剂组-0.1、OV组-0.1(P=0.88)。
- 肝硬度变化安慰剂组+0.1 kPa、OV组-4.0 kPa(P=0.15)。
- 牙齿和舌变色是OV最常见副作用(17.5%)。
关键数值与推荐
- 主要终点为SAP正常化。
- SAP正常化率:安慰剂5%,OV 6.7%(P=1.00)。
- SAP变化:安慰剂+1.2%,OV -21.9%(P=0.03)。
- Mayo PSC风险评分变化:安慰剂-0.1,OV -0.1(P=0.88)。
- 肝硬度变化:安慰剂+0.1 kPa,OV -4.0 kPa(P=0.15)。
临床怎么用
- 口服万古霉素不应常规用于改善PSC肝脏相关终点。
- 需关注牙齿和舌变色等副作用。
- 生活质量可能影响临床试验患者保留。
局限性
- 早期退出患者对基线健康评价较低(23.4% vs 54.5%,P<0.01)。
- 早期退出患者与完成研究者PSC预后特征相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease without approved medical therapies. We examined the efficacy and safety of oral vancomycin (OV) in those with PSC. METHODS: In this phase 3, 18-month, double-blind, placebo-controlled trial, we randomly assigned adults with PSC and a serum alkaline phosphatase (SAP) greater than 1.5 times the upper limit of normal to placebo or OV with dosages ranging from 125 to 375 mg 4 times daily pending biochemical response. The primary end point was normalization of SAP. RESULTS: Of the 82 patients who underwent randomization, 73 individuals had at least 1 outcome assessment. Individuals who withdrew early were less likely to rate their baseline health as excellent or very good (23.4% vs 54.5%, P < 0.01) despite having similar PSC prognostic features to those who completed the study. SAP normalization rates were similar (5% placebo, 6.7% OV, P = 1.00) after 18 months. Those who received OV had greater reduction in SAP (+1.2% placebo, -21.9% OV, P = 0.03). There were no differences in the changes in either the Mayo PSC risk score (-0.1 placebo, -0.1 OV, P = 0.88) or liver stiffness values (+0.1 kPa placebo, -4.0 kPa OV, P = 0.15). Discoloration of the teeth and tongue was the most common side effect of OV (17.5%). DISCUSSION: OV was not associated with clinically significant reductions in markers of PSC disease severity. Impairments in quality of life may influence patient retention in clinical trials.
引用
- Eaton JE, Clayton MW, Harnois DM, et al. Oral Vancomycin Is Not Associated With Meaningful Changes in Liver-Related End Points Among Adults With Primary Sclerosing Cholangitis: A Randomized, Placebo-Controlled Trial. Am J Gastroenterol. 2026. PMID: 42489629. doi:10.14309/ajg.0000000000004135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。